Trial Profile

An Open-Label, Single-Center, Phase 0, Microdose Study to Demonstrate Delivery of TTX-MC138-NODAGA-Cu64 to Radiographically Confirmed Metastases in Subjects With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase 0

Latest Information Update: 03 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TTX-MC138 (Primary)
Indications Solid tumours
Focus First in man; Pharmacokinetics; Proof of concept
Sponsors TransCode Therapeutics

Most Recent Events

04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
29 May 2024 According to a TransCode Therapeutics media release, full data analysis is ongoing and will be included in the final study report.
29 May 2024 Results published in the Transcode therapeutics Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com